Tighe Reardon compensation by year
Janux Therapeutics Summary Compensation Table · the one fiscal year held| Component | FY2024 |
|---|---|
| Salary | $0 |
| Bonus | $0 |
| Stock awards | $0 |
| Option awards | $7,913,496 |
| Non-equity incentive | $0 |
| Pension and deferred compensation | $0 |
| All other | $0 |
| Total | $7,913,496 |
Each year as stated in that year's proxy. A dash means the company reported no figure in that column. Source: Janux Therapeutics, Inc. DEF 14A filed April 25, 2025, accession 0000950170-25-058806, and prior-year filings.
How this page was built: the Janux Therapeutics, Inc. filed document, accession 0000950170-25-058806. Every figure is read from that document and cited to the page and table it appears in. Filed April 25, 2025.
Equity holdings
unvested awards at FY2024 year-end| Type | Unvested units | Value at year-end | Exercise price |
|---|---|---|---|
| Option | 20,016 | — | $10.59 |
| Option | 31,620 | — | $20.24 |
| Option | 41,250 | — | $14.02 |
| Option | 94,854 | — | $11.02 |
Per the Outstanding Equity Awards at Fiscal Year-End table in Janux Therapeutics, Inc.'s FY2024 proxy; value at the fiscal year-end close, as the company printed it.
Janux Therapeutics’s named executive officers, FY2024
as the company reported each| Named executive officer | Role | FY2024 total |
|---|---|---|
| David Campbell | President and Chief Executive Officer | $8,974,873 |
| Tighe Reardon · this page | Former Acting Chief Financial Officer | $7,913,496 |
| Byron Robinson | Chief Strategy Officer | $3,815,641 |
| Thomas DiRaimondo | Chief Scientific Officer | $3,414,644 |
The full Janux Therapeutics compensation record
free company briefThis page is one person within Janux Therapeutics's record. The company brief lists every named executive, each linking to their own page.
Peer companies
named in the Janux Therapeutics proxy · each links to its own free briefCompensation, the day it’s disclosed
The CompBrief Daily Digest lists the newest executive and director compensation disclosures as companies file them.
How this record is built
Every figure on this page is one figure from a public SEC filing, printed as the filing states it and cited to the document. Compensation totals are Janux Therapeutics's own disclosed totals, not summed by Velarion. Insider transactions are read from Form 4 filings and cover every line filed since the most recent proxy. Nothing is estimated by Velarion; where the company does not disclose a value the cell reads "—", and a section appears only where the company discloses the data. Corrections: records@velarion.ai.